Renal Denervation in Chronic Kidney Disease - RDN-CKD Study
NCT: NCT04264403 · COMPLETED
Brief Summary
RDN-CKD Study is a prospective, randomized (1:1, central randomization), double-blind (unblinded interventionalist and blinded study team at each center), sham controlled, multicenter feasibility study. The purpose of the RDN-CKD Study is to demonstrate that renal denervation (RDN) effectively reduces 24-h ambulatory BP in 80 patients with chronic kidney disease (CKD) stage 3a or 3b.
Frequently Asked Questions
What is Renal Denervation in Chronic Kidney Disease - RDN-CKD Study?
Renal Denervation in Chronic Kidney Disease - RDN-CKD Study is a clinical trial registered under NCT04264403. Current status: COMPLETED.
What is the status of NCT04264403?
The current status of NCT04264403 (Renal Denervation in Chronic Kidney Disease - RDN-CKD Study) is: COMPLETED.
When did Renal Denervation in Chronic Kidney Disease - RDN-CKD Study start?
Renal Denervation in Chronic Kidney Disease - RDN-CKD Study started on 2020-01-23.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.